Rice 360˚ Institute of Global Health's student innovators created projects and devices — from disinfecting devices and optimized intubation tools — that respond to challenges presented by COVID-19. Courtesy of Rice University

An annual program with Rice University and its partners in Africa had to do things differently in light of the COVID-19 pandemic. Not only did operations have to shift to a virtual approach, but the projects themselves instead addressed the needs created by the disease.

Rice 360˚ Institute for Global Health, which collaborates with the Malawi University of Science and Technology (MUST) and the University of Malawi, The Polytechnic (Poly), continued their annual programming virtually over six weeks. The collaboration brings students together to solve global health issues, and this year's issue to address was overwhelmingly COVID-19.

"We had to give a lot of thought to whether we might have to cancel the program, and that was really heartbreaking to think about," says Rice 360˚ Director Rebecca Richards-Kortum, professor of bioengineering, in a news release. "Back in those days of late March and early April, I never really imagined how wonderful the virtual internship program could be."

Thirteen undergraduate interns and eight teaching assistants from Rice and Malawi, worked on six different projects, and three were presented in an online event on July 16. Here were the projects that were presented.

  • A disinfecting system that has the capability to sterilize multiple N95 masks at once. The system uses ultraviolet lights that can kill the coronavirus in around 30 minutes. Alternatively, the project included a smaller version that could be powered by solar energy. Yankholanga Pelewelo of MUST, Carolyn Gonawamba of Poly, and Andrew Abikhaled and Bhavya Gopinath of Rice developed the technology.
  • A walk-in decontamination unit that can decontaminate up to 3,000 people per day. The team of interns developed a prototype that consisted of PVC frame covered in plastic with nozzles to spray disinfectant. The project has already received interest from labs and hospitals for the device. Team members included Brenald Dzonzi of Poly, Mwayi Yellewa of MUST, and Kaitlyn Heintzelman, Krystal Cheung, and Sana Mohamed of Rice.
  • A redesigned intubation box that gives doctors better access to patients during the procedure. More than half of the 3,000 health care workers who have died from the coronavirus were doctors who focused on respiratory procedures, the team pointed out, and this daunting fact calls for redesigned tools. In total, the student innovators pitched three different designs that each included armholes in the sides, with a third hole on top to let a clinician or nurse assist with the procedure. The student team consisted of Chikumbutso Walani of Poly, Ruth Mtuwa of MUST, and Lauren Payne and Austin Hwang of Rice.

The other three projects included in the program but didn't present were designs for face shields, a hand sanitizer station and a contactless temperature monitor. All of the projects were led by teaching assistants Aubrey Chikunda and Chisomo Mukoka from MUST; Hannah Andersen, Nimisha Krishnaswamy, Alex Lammers and Ben Zaltsman of Rice; and Hope Chilunga and Francis Chilomo from Poly.

While pivoting the program to virtual comes with its challenges, Maria Oden — a professor of bioengineering, director of Rice's Oshman Engineering Design Kitchen and director of Rice 360˚ — recognizes the opportunities it provides as well.

"It would have been easy and understandable to cancel this internship, but that's not what happened, and look what the result was," Oden says in the release. "Over 90 people have tuned in to see the work of the interns. That's something we've never achieved with our in-person internships. We can learn from this experience."


Rice 360° Virtual Internship Highlights – Summer 2020www.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."